MAIA Biotechnology, Inc. MAIA 深 沪
等待开盘 08-06 09:30:00 美东时间
1.40
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.40
- 总市值 8512.11万
- 52周最高 3.19
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.87
- 委 比 0.00%
- 总股本 6080.08万
- 历史最高 9.64
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.82
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MA...
07-08 21:53
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead can...
06-25 20:10
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were purchased by Dr. Smith on
06-02 21:54
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 12.5 percent increase over losses of $(0.16) per share from
05-11 21:31
MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S.
04-16 21:23
MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial;
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
03-31 21:19
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of $(0.12) per share from
03-24 06:11
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
MAIA Biotechnology Highlights Phase 3 Momentum And FDA Fast Track For Ateganosine In Third-Line NSCLC
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast Track designation offers clear pathway for ateganosine as third-line therapy
02-24 21:47
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nuwellis (NASDAQ:NUWE) shares rose 81.5% to $3.9 during Tuesday's regu...
01-28 01:05
